Braun Stacey Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-324,344
| Closed | -$11.9M | – | 143 |
|
|
2020
Q4 | $11.9M | Buy |
324,344
+15,500
| +5% | +$569K | 0.54% | 89 |
|
|
2020
Q3 | $10.8M | Sell |
308,844
-1,681
| -0.5% | -$58.9K | 0.58% | 87 |
|
|
2020
Q2 | $9.63M | Sell |
310,525
-622
| -0.2% | -$21.1K | 0.55% | 90 |
|
|
2020
Q1 | $9.63M | Sell |
311,147
-61,827
| -17% | -$2.11M | 0.73% | 69 |
|
|
2019
Q4 | $13.9M | Buy |
372,974
+8,168
| +2% | +$291K | 0.77% | 73 |
|
|
2019
Q3 | $12.4M | Buy |
364,806
+400
| +0.1% | +$14.5K | 0.78% | 73 |
|
|
2019
Q2 | $15M | Sell |
364,406
-585
| -0.2% | -$23.2K | 0.96% | 49 |
|
|
2019
Q1 | $14.7M | Buy |
364,991
+7,963
| +2% | +$319K | 0.98% | 47 |
|
|
2018
Q4 | $14.8M | Sell |
357,028
-1,760
| -0.5% | -$73.1K | 1.17% | 22 |
|
|
2018
Q3 | $15M | Sell |
358,788
-591
| -0.2% | -$22.8K | 0.96% | 47 |
|
|
2018
Q2 | $12.4M | Sell |
359,379
-136,487
| -28% | -$4.66M | 0.84% | 61 |
|
|
2018
Q1 | $16.7M | Buy |
495,866
+1,091
| +0.2% | +$37.5K | 1.15% | 24 |
|
|
2017
Q4 | $17M | Buy |
494,775
+66,260
| +15% | +$2.26M | 1.14% | 26 |
|
|
2017
Q3 | $14.5M | Sell |
428,515
-40,737
| -9% | -$1.31M | 0.99% | 44 |
|
|
2017
Q2 | $15M | Sell |
469,252
-26,335
| -5% | -$830K | 0.97% | 49 |
|
|
2017
Q1 | $16.1M | Sell |
495,587
-41,617
| -8% | -$1.31M | 1.02% | 41 |
|
|
2016
Q4 | $16.6M | Sell |
537,204
-16,326
| -3% | -$498K | 1.09% | 29 |
|
|
2016
Q3 | $17.8M | Sell |
553,530
-2,414
| -0.4% | -$80.7K | 1.13% | 24 |
|
|
2016
Q2 | $18.6M | Sell |
555,944
-27,285
| -5% | -$871K | 1.2% | 18 |
|
|
2016
Q1 | $16.4M | Sell |
583,229
-59,368
| -9% | -$1.7M | 1.07% | 33 |
|
|
2015
Q4 | $19.7M | Buy |
642,597
+23,583
| +4% | +$742K | 1.24% | 16 |
|
|
2015
Q3 | $18.4M | Sell |
619,014
-237,401
| -28% | -$7.61M | 1.24% | 15 |
|
|
2015
Q2 | $27.2M | Buy |
856,415
+207,370
| +32% | +$6.76M | 1.16% | 10 |
|
|
2015
Q1 | $21.4M | Sell |
649,045
-2,345
| -0.4% | -$74.6K | 1.26% | 13 |
|
|
2014
Q4 | $19.3M | Sell |
651,390
-437
| -0.1% | -$12.5K | 1.17% | 21 |
|
|
2014
Q3 | $18.3M | Sell |
651,827
-6,504
| -1% | -$183K | 1.13% | 29 |
|
|
2014
Q2 | $18.5M | Sell |
658,331
-12,906
| -2% | -$368K | 1.1% | 33 |
|
|
2014
Q1 | $20.5M | Sell |
671,237
-11,253
| -2% | -$336K | 1.2% | 23 |
|
|
2013
Q4 | $19.8M | Sell |
682,490
-26,380
| -4% | -$768K | 1.14% | 27 |
|
|
2013
Q3 | $19.3M | Sell |
708,870
-42,523
| -6% | -$1.16M | 1.19% | 22 |
|
|
2013
Q2 | $20M | Buy |
+751,393
| New | +$20.8M | 1.26% | 16 |
|
Other funds holding PFE
Braun Stacey Associates's PFE Position: Q1 2021 in Review
Braun Stacey Associates sold out of Pfizer (PFE) in Q1 2021, closing a stake of 324,344 shares — an estimated $11.9M sold.
Braun Stacey Associates first reported a position in PFE in Q2 2013 and held it in 31 quarters. The position peaked at $27.2M in Q2 2015. 2,675 funds tracked by Wall St. Rank hold PFE as of Q1 2021.
- Braun Stacey Associates reported no remaining Pfizer position as of Q1 2021 after selling out during the quarter.
- Braun Stacey Associates sold 324,344 Pfizer shares in Q1 2021, an estimated $11.9M.
- Braun Stacey Associates first reported a position in Pfizer in Q2 2013 and held it in 31 quarters.
- Braun Stacey Associates's Pfizer position peaked at $27.2M in Q2 2015.
- 2,675 funds tracked by Wall St. Rank held Pfizer as of Q1 2021.
Based on Braun Stacey Associates's 13F filing for Q1 2021, filed 28 Apr 2021.